ImmunomeIMNM +2.83%44 OCF Yield % is -8.69 as of Jun. 28, 2026. GuruFocus rates IMNM with a GF Score™ of 44/100 and a GF Value™ of $2.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Immunome ranks worse than 50.6% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Immunome OCF Yield % Related Terms
Immunome OCF Yield % Historical Data
* Premium members only.
The historical data trend for Immunome's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunome's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunome OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunome's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Immunome's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunome (IMNM) has a OCF Yield % of -8.69 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Immunome and its competitors. According to the industry distribution chart, Immunome ranks #717 out of 1417 companies in the Biotechnology industry, placing it in the top 50.6%.
Is Immunome's OCF Yield % too high?
Immunome's current OCF Yield % is -8.69. Based on the distribution chart, Immunome ranks #717 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immunome has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunome's OCF Yield % compare to CLDX and ELVN?
According to the Biotechnology industry distribution chart, Immunome ranks #717 out of 1417 companies for OCF Yield %. This places Immunome in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Immunome and its competitors. Immunome's current OCF Yield % is -8.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunome stock overvalued right now?
Based on GuruFocus' analysis, Immunome (IMNM) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.02, compared to a current price of $19.97 — trading 888.6% above its estimated fair value. The current OCF Yield % is -8.69. Immunome's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Immunome (IMNM), the current OCF Yield % is -8.69 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunome (IMNM) Overvalued in 2026?
Based on GuruFocus' analysis, Immunome stock appears to be overvalued.
The current stock price of $19.97 is trading 888.6% above its estimated GF Value™ of $2.02.
GuruFocus considers Immunome to be Significantly Overvalued.
Key valuation signals for IMNM:
OCF Yield %: -8.69
GF Value™: $2.02 vs. price of $19.97 (888.6% above fair value)
No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score
Get the complete analysis for IMNM
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMNM has been successfully added to your 
